CA2219904A1 - Nouvelles compositions adjuvantes et formulations de vaccins les comprenant - Google Patents

Nouvelles compositions adjuvantes et formulations de vaccins les comprenant Download PDF

Info

Publication number
CA2219904A1
CA2219904A1 CA002219904A CA2219904A CA2219904A1 CA 2219904 A1 CA2219904 A1 CA 2219904A1 CA 002219904 A CA002219904 A CA 002219904A CA 2219904 A CA2219904 A CA 2219904A CA 2219904 A1 CA2219904 A1 CA 2219904A1
Authority
CA
Canada
Prior art keywords
polysaccharide
adjuvant
phospholipid
antigen
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002219904A
Other languages
English (en)
Inventor
Indu Parikh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Triangle Pharmaceuticals Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2219904A1 publication Critical patent/CA2219904A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un adjuvant destiné à être administré à un animal hôte pour renforcer la réponse immune, comprenant un conjugué de polysaccharide-phospholipide, dont la fraction polysaccharide peut, par exemple, comprendre une glucane, un chitosane ou un polysaccharide alginate modifié, conjugué avec un phospholipide. L'adjuvant peut avantageusement être formulé avec un antigène pour produire un vaccin thérapeutique destiné à une variété d'états pathologiques et/ou à une variété de conditions physiologiques.
CA002219904A 1995-06-26 1996-06-26 Nouvelles compositions adjuvantes et formulations de vaccins les comprenant Abandoned CA2219904A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46496995A 1995-06-26 1995-06-26
US464,969 1995-06-26

Publications (1)

Publication Number Publication Date
CA2219904A1 true CA2219904A1 (fr) 1997-01-16

Family

ID=23846008

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002219904A Abandoned CA2219904A1 (fr) 1995-06-26 1996-06-26 Nouvelles compositions adjuvantes et formulations de vaccins les comprenant

Country Status (6)

Country Link
EP (1) EP0857059A1 (fr)
JP (1) JP2001523216A (fr)
KR (1) KR19990028383A (fr)
AU (1) AU6400796A (fr)
CA (1) CA2219904A1 (fr)
WO (1) WO1997001330A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
GB2325233B (en) * 1997-05-16 2001-07-18 Norsk Hydro As Substrates having bound polysaccharides and bacterial nucleic acids
US8076312B2 (en) 2000-01-10 2011-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Use of lipid conjugates in the treatment of disease
US8501701B2 (en) 2000-01-10 2013-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US20060189568A1 (en) 2000-01-10 2006-08-24 Saul Yedgar Use of lipid conjugates in the treatment of infection
US7608598B2 (en) 2000-01-10 2009-10-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of conjunctivitis
US8916539B2 (en) 2000-01-10 2014-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US7393938B2 (en) 2000-01-10 2008-07-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7141552B2 (en) 2000-01-10 2006-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7893226B2 (en) 2004-09-29 2011-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
WO2001051003A2 (fr) * 2000-01-10 2001-07-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Utilisation de conjugues de lipides dans le traitement de maladies
US8304395B2 (en) 2000-01-10 2012-11-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Lipid conjugates in the treatment of disease
US9040078B2 (en) 2000-01-10 2015-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases of the nervous system
US7101859B2 (en) 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7772196B2 (en) 2000-01-10 2010-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7811999B2 (en) 2000-01-10 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
US8883761B2 (en) 2001-01-10 2014-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases associated with vasculature
CN100391439C (zh) * 2001-04-27 2008-06-04 味之素株式会社 免疫增强剂
KR100426636B1 (ko) * 2001-05-18 2004-04-08 한국과학기술연구원 주사 가능한 젤 상의 조성물 및 그의 제조방법
US8859524B2 (en) 2005-11-17 2014-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of chronic rhinosinusitis
US8906882B2 (en) 2005-11-17 2014-12-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of allergic rhinitis
CA2705785A1 (fr) 2006-11-14 2008-05-22 Saul Yedgar Utilisation de conjugues lipidiques dans le traitement de maladies ou de troubles oculaires
EP2429532A4 (fr) 2009-05-11 2015-05-27 Yissum Res Dev Co Conjugués lipides/polymères, leur préparation et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204098A (en) * 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US5057503A (en) * 1989-01-23 1991-10-15 The Brigham And Women's Hospital Derivativized polysaccharides with biologic activity, method of their isolation, and uses therefor
US5189028A (en) * 1989-02-20 1993-02-23 Taito Co., Ltd. Composition and method to enhance the efficacy of a fish vaccine and to stimulate the immune system of fish
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes

Also Published As

Publication number Publication date
WO1997001330A1 (fr) 1997-01-16
EP0857059A1 (fr) 1998-08-12
KR19990028383A (ko) 1999-04-15
JP2001523216A (ja) 2001-11-20
AU6400796A (en) 1997-01-30

Similar Documents

Publication Publication Date Title
US5785975A (en) Adjuvant compositions and vaccine formulations comprising same
CA2219904A1 (fr) Nouvelles compositions adjuvantes et formulations de vaccins les comprenant
De Serrano et al. Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
EP1333858B1 (fr) Vaccins a reponse immunitaire accrue et leurs procedes de preparation
US5759572A (en) Liposome with oligosaccharide on surface
US6004534A (en) Targeted polymerized liposomes for improved drug delivery
JP5769624B2 (ja) ワクチン
US6060082A (en) Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
Wassef et al. Liposomes as carriers for vaccines
JP5344558B2 (ja) カチオン性ナノゲルを用いる粘膜ワクチン
US5912000A (en) Chitosan induced immunopotentiation
JP3365635B2 (ja) キトサン誘導性免疫強化
RU2107493C1 (ru) Липосомы, осуществляющие тимус-зависимую помощь "слабым" антигенам, используемым для приготовления вакцины
EP2255831A1 (fr) Construction de diépitopes à base de liposomes
JPH05507498A (ja) 改良されたアジュバントおよびワクチン
WO2007039583A1 (fr) Compositions vaccinales liposomales comprenant un antigene polysaccharide et un adjuvant proteique
US6562801B1 (en) PpGpp and pppGpp as immunomodulatory agents
JP4217418B2 (ja) キトサン誘導性免疫強化
JP2000504350A (ja) キトサン誘導性免疫強化

Legal Events

Date Code Title Description
FZDE Dead